Focus:
Deal News
-
11 August 2020
Verastem to divest Copiktra rights to Secura Bio for up to $381m
Biopharmaceutical company Verastem has signed a definitive agreement to divest the global commercial and development rights for Copiktra (duvelisib) to Secura Bio in a deal valued at up to $381m.
-
10 August 2020
Pfizer signs multi-year deal to manufacture Gilead’s remdesivir
Pfizer has entered into a multi-year agreement to manufacture and supply Gilead Science’s experimental antiviral drug remdesivir, for the treatment of Covid-19 patients.
-
10 August 2020
Novavax partners with Takeda to develop Covid-19 vaccine in Japan
US-based biotechnology firm Novavax has partnered with Takeda Pharmaceutical to develop, manufacture and commercialise its Covid-19 vaccine candidate, NVX‑CoV2373, in Japan.
-
7 August 2020
Biogen and Denali sign Parkinson’s drug deal worth $2bn
Biogen has entered into a binding agreement with Denali Therapeutics to jointly develop and commercialise therapeutics for Parkinson’s disease.
-
7 August 2020
AstraZeneca signs first deal to supply Covid-19 vaccine in China
AstraZeneca has partnered with Shenzhen Kangtai Biological Products to manufacture its Covid-19 vaccine candidate in mainland China, marking its first deal to supply in the country.
-
5 August 2020
Teva enters biosimilar commercialisation partnership with Alvotech
Israel-based Teva Pharmaceutical has formed an exclusive strategic collaboration with Alvotech to commercialise five biosimilar candidates in the US.
-
5 August 2020
AstraZeneca to develop Redx’s drug for fibrotic diseases
AstraZeneca has entered into an agreement with UK-based biotechnology company Redx Pharma to licence a porcupine inhibitor, named RXC006, for fibrotic diseases.
-
4 August 2020
Merck licences NASH drug efinopegdutide from Hanmi
Merck (MSD) has signed an exclusive licensing agreement with Hanmi Pharmaceutical to develop, manufacture and commercialise efinopegdutide (formerly HM12525A) to treat nonalcoholic steatohepatitis (NASH).
-
31 July 2020
Novartis partners with Sangamo on genomic therapies
Novartis has signed an exclusive, global licensing collaboration agreement with Sangamo Therapeutics to develop and commercialise genomic therapies for neurodevelopmental disorders, including autism.
-
30 July 2020
Intravacc and Celonic team up to develop Covid-19 vaccine
Intravacc has partnered with contract development and manufacturing organisation (CDMO) Celonic Group for the design, development and production of a Covid-19 vaccine.